{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Natural+killer+cell+therapy&page=3", "query": { "intervention": "Natural killer cell therapy", "page": 3 }, "page_size": 10 }, "pagination": { "page": 3, "page_size": 10, "total_count": 165, "total_pages": 17, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Natural+killer+cell+therapy&page=4&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Natural+killer+cell+therapy&page=2&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-02T05:04:44.387Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT06769126", "title": "Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM Study", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Extensive Stage Lung Small Cell Carcinoma", "Lung Small Cell Carcinoma, A Subtype", "Lung Small Cell Carcinoma, I Subtype", "Lung Small Cell Carcinoma, N Subtype", "Lung Small Cell Carcinoma, P Subtype" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Ceralasertib", "type": "DRUG" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Durvalumab", "type": "BIOLOGICAL" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Magnetic Resonance Imaging", "type": "PROCEDURE" }, { "name": "Monalizumab", "type": "BIOLOGICAL" }, { "name": "Platinum Compound", "type": "DRUG" }, { "name": "Positron Emission Tomography", "type": "PROCEDURE" }, { "name": "Saruparib", "type": "DRUG" }, { "name": "Thoracic Radiation Therapy", "type": "RADIATION" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL", "RADIATION" ], "sponsor": "SWOG Cancer Research Network", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 900, "start_date": "2025-11-06", "completion_date": "2029-12-31", "has_results": false, "last_update_posted_date": "2026-03-30", "last_synced_at": "2026-10-02T05:04:44.387Z", "location_count": 148, "location_summary": "Loma Linda, California • Rancho Mirage, California • Sacramento, California + 118 more", "locations": [ { "city": "Loma Linda", "state": "California" }, { "city": "Rancho Mirage", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Colorado Springs", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT06769126" }, { "nct_id": "NCT03019640", "title": "Umbilical Cord Blood NK Cells, Rituximab, High-Dose Chemotherapy, and Stem Cell Transplant in Treating Patients With Recurrent or Refractory B-Cell Non-Hodgkin's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Mantle Cell Lymphoma", "Recurrent Diffuse Large B-Cell Lymphoma", "Recurrent Follicular Lymphoma", "Recurrent Indolent Adult Non-Hodgkin Lymphoma", "Refractory Diffuse Large B-Cell Lymphoma", "Refractory Follicular Lymphoma", "Refractory Indolent Adult Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "Autologous Hematopoietic Stem Cell Transplantation", "type": "PROCEDURE" }, { "name": "Carmustine", "type": "DRUG" }, { "name": "Cord Blood-derived Expanded Allogeneic Natural Killer Cells", "type": "BIOLOGICAL" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Filgrastim", "type": "BIOLOGICAL" }, { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Melphalan", "type": "DRUG" }, { "name": "Rituximab", "type": "BIOLOGICAL" } ], "intervention_types": [ "PROCEDURE", "DRUG", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "15 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "15 Years to 70 Years" }, "enrollment_count": 22, "start_date": "2017-10-10", "completion_date": "2021-08-16", "has_results": true, "last_update_posted_date": "2023-02-16", "last_synced_at": "2026-10-02T05:04:44.387Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT03019640" }, { "nct_id": "NCT01700946", "title": "Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent B-Cell Childhood Acute Lymphoblastic Leukemia", "Recurrent Childhood B-Lymphoblastic Lymphoma" ], "interventions": [ { "name": "dexamethasone", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" }, { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "clofarabine", "type": "DRUG" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "aldesleukin", "type": "BIOLOGICAL" }, { "name": "pegaspargase", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "mercaptopurine", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "mitoxantrone", "type": "DRUG" }, { "name": "teniposide", "type": "DRUG" }, { "name": "vinblastine", "type": "DRUG" }, { "name": "natural killer cell infusion", "type": "BIOLOGICAL" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "therapeutic hydrocortisone", "type": "DRUG" }, { "name": "allogeneic hematopoietic stem cell transplantation", "type": "PROCEDURE" }, { "name": "CliniMACS", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "OTHER", "PROCEDURE", "DEVICE" ], "sponsor": "St. Jude Children's Research Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 80, "start_date": "2013-04-15", "completion_date": "2021-07-24", "has_results": true, "last_update_posted_date": "2022-09-28", "last_synced_at": "2026-10-02T05:04:44.387Z", "location_count": 3, "location_summary": "San Diego, California • Memphis, Tennessee • Fort Worth, Texas", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Memphis", "state": "Tennessee" }, { "city": "Fort Worth", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01700946" }, { "nct_id": "NCT03735589", "title": "Specialized Immune Cells (nCTLs) and a Vaccine (Alpha-type-1 Polarized Dendritic Cells) in Treating Patients With Stage II-IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Stage II Fallopian Tube Cancer AJCC v8", "Stage II Ovarian Cancer AJCC v8", "Stage II Primary Peritoneal Cancer AJCC v8", "Stage IIA Fallopian Tube Cancer AJCC v8", "Stage IIA Ovarian Cancer AJCC v8", "Stage IIA Primary Peritoneal Cancer AJCC v8", "Stage IIB Fallopian Tube Cancer AJCC v8", "Stage IIB Ovarian Cancer AJCC v8", "Stage IIB Primary Peritoneal Cancer AJCC v8", "Stage III Fallopian Tube Cancer AJCC v8", "Stage III Ovarian Cancer AJCC v8", "Stage III Primary Peritoneal Cancer AJCC v8", "Stage IIIA Fallopian Tube Cancer AJCC v8", "Stage IIIA Ovarian Cancer AJCC v8", "Stage IIIA Primary Peritoneal Cancer AJCC v8", "Stage IIIA1 Fallopian Tube Cancer AJCC v8", "Stage IIIA1 Ovarian Cancer AJCC v8", "Stage IIIA2 Fallopian Tube Cancer AJCC v8", "Stage IIIA2 Ovarian Cancer AJCC v8", "Stage IIIB Fallopian Tube Cancer AJCC v8", "Stage IIIB Ovarian Cancer AJCC v8", "Stage IIIB Primary Peritoneal Cancer AJCC v8", "Stage IIIC Fallopian Tube Cancer AJCC v8", "Stage IIIC Ovarian Cancer AJCC v8", "Stage IIIC Primary Peritoneal Cancer AJCC v8", "Stage IV Fallopian Tube Cancer AJCC v8", "Stage IV Ovarian Cancer AJCC v8", "Stage IV Primary Peritoneal Cancer AJCC v8", "Stage IVA Fallopian Tube Cancer AJCC v8", "Stage IVA Ovarian Cancer AJCC v8", "Stage IVA Primary Peritoneal Cancer AJCC v8", "Stage IVB Fallopian Tube Cancer AJCC v8", "Stage IVB Ovarian Cancer AJCC v8", "Stage IVB Primary Peritoneal Cancer AJCC v8" ], "interventions": [ { "name": "Alpha-type-1 Polarized Dendritic Cells", "type": "BIOLOGICAL" }, { "name": "Autologous Natural Killer Cell-like CTLs", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Roswell Park Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "FEMALE", "summary": "18 Years and older · Female only" }, "enrollment_count": 0, "start_date": "2023-12-15", "completion_date": "2025-12-01", "has_results": false, "last_update_posted_date": "2023-11-22", "last_synced_at": "2026-10-02T05:04:44.387Z", "location_count": 1, "location_summary": "Buffalo, New York", "locations": [ { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03735589" }, { "nct_id": "NCT07011004", "title": "A Study of Natural Killer Cells in Combination With Atezolizumab in People With Acute Myelogenous Leukemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia Refractory", "Acute Myeloid Leukemia, in Relapse" ], "interventions": [ { "name": "Cytokine Induced Memory-Like Natural Killer Cells", "type": "BIOLOGICAL" }, { "name": "Atezolizumb", "type": "BIOLOGICAL" }, { "name": "CIML-NK cell therapy", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 18, "start_date": "2025-05-30", "completion_date": "2028-05", "has_results": false, "last_update_posted_date": "2026-06-17", "last_synced_at": "2026-10-02T05:04:44.387Z", "location_count": 7, "location_summary": "Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more", "locations": [ { "city": "Basking Ridge", "state": "New Jersey" }, { "city": "Middletown", "state": "New Jersey" }, { "city": "Montvale", "state": "New Jersey" }, { "city": "Commack", "state": "New York" }, { "city": "Harrison", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07011004" }, { "nct_id": "NCT04634435", "title": "Autologous Memory-like NK Cell Therapy With BHV-1100 and Low Dose IL-2 in Multiple Myeloma Patients", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Multiple Myeloma" ], "interventions": [ { "name": "BHV-1100 plus cytokine induced memory-like (CIML) NK cells plus IVIG and low dose IL-2", "type": "COMBINATION_PRODUCT" } ], "intervention_types": [ "COMBINATION_PRODUCT" ], "sponsor": "Biohaven Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 7, "start_date": "2021-10-21", "completion_date": "2025-01-10", "has_results": false, "last_update_posted_date": "2025-01-20", "last_synced_at": "2026-10-02T05:04:44.387Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT04634435" }, { "nct_id": "NCT02271711", "title": "Expanded Natural Killer Cell Infusion in Treating Younger Patients With Recurrent/Refractory Brain Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Recurrent Childhood Medulloblastoma", "Recurrent Ependymoma", "Recurrent Medulloblastoma" ], "interventions": [ { "name": "Laboratory Biomarker Analysis", "type": "OTHER" }, { "name": "Natural Killer Cell Therapy", "type": "BIOLOGICAL" } ], "intervention_types": [ "OTHER", "BIOLOGICAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 12, "start_date": "2015-03-17", "completion_date": "2020-08-28", "has_results": false, "last_update_posted_date": "2020-09-02", "last_synced_at": "2026-10-02T05:04:44.387Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02271711" }, { "nct_id": "NCT00900809", "title": "QUILT-3.018: Neukoplast™ (NK-92) for the Treatment of Refractory or Relapsed Acute Myeloid Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Acute Myeloid Leukemia" ], "interventions": [ { "name": "Neukoplast™ (NK-92)", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "ImmunityBio, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2014-05-12", "completion_date": "2015-06-02", "has_results": false, "last_update_posted_date": "2022-04-05", "last_synced_at": "2026-10-02T05:04:44.387Z", "location_count": 1, "location_summary": "Pittsburgh, Pennsylvania", "locations": [ { "city": "Pittsburgh", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00900809" }, { "nct_id": "NCT02145039", "title": "Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Acute Leukemias", "Burkitt's Lymphoma", "Chronic Myelogenous Leukemia" ], "interventions": [ { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Total Body Irradiation", "type": "RADIATION" }, { "name": "Haploidentical stem cell transplant", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "RADIATION", "BIOLOGICAL" ], "sponsor": "Masonic Cancer Center, University of Minnesota", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "74 Years", "sex": "ALL", "summary": "Up to 74 Years" }, "enrollment_count": 2, "start_date": "2014-10", "completion_date": "2019-01", "has_results": true, "last_update_posted_date": "2019-12-26", "last_synced_at": "2026-10-02T05:04:44.387Z", "location_count": 1, "location_summary": "Minneapolis, Minnesota", "locations": [ { "city": "Minneapolis", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT02145039" }, { "nct_id": "NCT00877110", "title": "Anti-GD2 3F8 Antibody and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Neuroblastoma", "Bone Marrow, Sympathetic Nervous System" ], "interventions": [ { "name": "cyclophosphamide, vincristine, topotecan ,allogeneic NK cells & 3F8", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": null, "sex": "ALL", "summary": "Not listed" }, "enrollment_count": 71, "start_date": "2009-04-02", "completion_date": "2019-01-07", "has_results": false, "last_update_posted_date": "2019-01-10", "last_synced_at": "2026-10-02T05:04:44.387Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00877110" } ] }